Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Farmers Insurance
US Department of Justice
Covington
McKinsey
Fuji

Generated: July 17, 2019

DrugPatentWatch Database Preview

Patent: 9,180,214

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,180,214
Title:Gonadotropin-releasing hormone receptor-targeting peptides and their use to treat and diagnose cancer
Abstract: The present invention is directed to novel non-invasive diagnostic tools/compounds to image and treat cancers, especially cancers which overexpress GnRH such as breast cancer, prostate cancer and melanoma, among others, including metastatic breast cancer, prostate cancer and/or melanoma among numerous others in vivo. The novel imaging probes are capable of detecting cancerous cells, as well as their metastatic spread in tissues. The novel probes of the present invention will also be useful to initiate therapy for breast and/or prostate cancer, among other cancers, as well as monitor patients\' response to chemotherapy treatments and other interventions or therapies used in the treatment of cancer, including metastatic cancer as otherwise described herein. Compounds according to the present invention may be used as diagnostic tools for diagnosing cancer as well as therapeutic agents for treating cancer and related secondary disease states and conditions.
Inventor(s): Miao; Yubin (Albuquerque, NM)
Assignee: STC.UNM (Albuquerque, NM)
Application Number:13/447,918
Patent Claims:see list of patent claims

Details for Patent 9,180,214

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Bristol Myers Squibb YERVOY ipilimumab INJECTABLE; INJECTION 125377 001 2011-03-25 ➤ Sign Up STC.UNM (Albuquerque, NM) ➤ Sign Up RX search
Glaxo Grp Ltd ARZERRA ofatumumab INJECTABLE; INJECTION 125326 001 2009-10-26 ➤ Sign Up STC.UNM (Albuquerque, NM) ➤ Sign Up RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27 ➤ Sign Up STC.UNM (Albuquerque, NM) ➤ Sign Up RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27 ➤ Sign Up STC.UNM (Albuquerque, NM) ➤ Sign Up RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Moodys
Cipla
Healthtrust
Mallinckrodt
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.